Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 7/20 | 0.70 |
| ▸ | NOS3 | P29474 | 6/20 | 0.70 |
| ▸ | NOS1 | P29475 | 5/20 | 0.70 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4547885 | 0.87 | NOS2 (0.61) | NOS2NOS3NOS1TSHRCYP3A4 | |
| SCHEMBL16282388 | 0.83 | NOS3 (0.57) | NOS2NOS3NOS1TSHRCYP3A4 | |
| SCHEMBL9228677 | 0.83 | NOS2 (0.57) | NOS2NOS3NOS1TSHRCYP3A4 | |
| SCHEMBL15980614 | 0.83 | NOS3 (0.57) | NOS2NOS3NOS1TSHRCYP3A4 | |
| SCHEMBL7050708 | 0.83 | NOS2 (1.00) | NOS2NOS3NOS1 | |
| SCHEMBL18611537 | 0.83 | NOS3 (0.57) | NOS2NOS3NOS1TSHRCYP3A4 | |
| SCHEMBL12093720 | 0.79 | NOS3 (0.53) | NOS2NOS3NOS1CYP1A2ALDH1A1 | |
| SCHEMBL12460586 | 0.79 | NOS3 (0.53) | NOS2NOS3NOS1TSHRCYP3A4 | |
| SCHEMBL23443723 | 0.78 | NOS2 (0.52) | NOS2NOS3NOS1TSHRCYP3A4 | |
| SCHEMBL21212137 | 0.78 | CYP3A4 (0.58) | NOS2NOS3NOS1TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029347-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-01-26 | — | — | US | disclosed |
| US-20220168315-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VIOGEN BIOSCIENCES, LLC | 2022-06-02 | — | — | US | disclosed |
| US-10966985-B2 | Macrocyclic compounds as ROS1 kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20190151322-A1 | MACROCYCLIC COMPOUNDS AS ROS1 KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-05-23 | — | — | US | disclosed |
| US-20190076436-A1 | MACROCYCLIC COMPOUNDS AS ROS1 KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-03-14 | — | — | US | disclosed |
| US-9315593-B2 | Catalyst systems comprising pyridyldiamido transition metal complexes and chain transfer agent and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9290519-B2 | Pyridyldiamido transition metal complexes, production and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9260552-B2 | Process to produce polymers from pyridyldiamido transition metal complexes and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150141590-A1 | Process to Produce Polymers from Pyridyldiamido Transition Metal Complexes and Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150141601-A1 | Pyridyldiamido Transition Metal Complexes, Production and Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2015-05-21 | — | — | US | disclosed |
| US-20110098241-A1 | RAPAMYCIN ANALOGS AS ANTI-CANCER AGENTS | PONIARD PHARMACEUTICALS, INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110098241-A1 | RAPAMYCIN ANALOGS AS ANTI-CANCER AGENTS | PONIARD PHARMACEUTICALS, INC. | 2011-04-28 | — | — | US | disclosed |
| EP-1445260-A1 | Method of immobilising of chemical compounds to solid phases | Jerini AG (DE) | 2004-08-11 | — | — | EP | disclosed |
| US-5864022-A | Process for the manufacture of 3-amino-substituted glycosylated bile acids | INTERCARDIA, INC. (US) | 1999-01-26 | — | — | US | disclosed |
| EP-0766690-A4 | PROCESS FOR THE MANUFACTURE OF 3-AMINO-SUBSTITUTED GLYCOSYLATED BILE ACIDS | TRANSCELL TECHNOLOGIES INC (US) | 1998-12-30 | — | — | EP | disclosed |
| US-5693770-A | Process for the manufacture of 3-amino-substituted glycosylated bile acids | TRANSCELL TECHNOLOGIES, INC. (US) | 1997-12-02 | — | — | US | disclosed |
| US-5627270-A | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same | TRUSTEES OF PRINCETON UNIVERSITY (US) | 1997-05-06 | — | — | US | disclosed |
| EP-0766690-A1 | PROCESS FOR THE MANUFACTURE OF 3-AMINO-SUBSTITUTED GLYCOSYLATED BILE ACIDS | TRANSCELL TECHNOLOGIES, INC. (US) | 1997-04-09 | — | — | EP | disclosed |
| US-5585470-A | Process for the manufacture of 3-amino-substituted glycosylated bile acids | TRANSCELL TECHNOLOGIES, INC. (US) | 1996-12-17 | — | — | US | disclosed |
| WO-1996000230-A1 | PROCESS FOR THE MANUFACTURE OF 3-AMINO-SUBSTITUTED GLYCOSYLATED BILE ACIDS | TRANSCELL TECHNOLOGIES, INC. (US) | 1996-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098241-A1 | RAPAMYCIN ANALOGS AS ANTI-CANCER AGENTS | RICTOR, MTOR, RPTOR | NOS2 4656/4885NOS3 4599/4885NOS1 4575/4885 |
| US-20230029347-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, OSBP | NOS2 1198/4885NOS3 2104/4885NOS1 722/4885 |
| US-20220168315-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | IL15, IL17A, IL2 | NOS2 1238/4885NOS3 1496/4885NOS1 2475/4885 |
| US-10966985-B2 | Macrocyclic compounds as ROS1 kinase inhibitors | ROS1, MAP3K1, MAP3K19 | NOS2 2304/4885NOS3 1830/4885NOS1 1305/4885 |
| US-20190151322-A1 | MACROCYCLIC COMPOUNDS AS ROS1 KINASE INHIBITORS | ROS1, MAP3K1, MAP3K19 | NOS2 2304/4885NOS3 1830/4885NOS1 1305/4885 |
| US-20190076436-A1 | MACROCYCLIC COMPOUNDS AS ROS1 KINASE INHIBITORS | ROS1, MAP3K1, MAP3K19 | NOS2 2304/4885NOS3 1830/4885NOS1 1305/4885 |
| US-20150141601-A1 | Pyridyldiamido Transition Metal Complexes, Production and Use Thereof | PNPO, PLPBP, PDXK | NOS2 944/4885NOS3 1101/4885NOS1 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.